P

D

PAU , David

Last name: PAU

First name: David

August 13, 2022 (v1)

Journal article

Metadata-only

Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study

Manchon, Eric Laplaud, David Vukusic, Sandra

Background: Ocrelizumab, a humanized anti-CD20 monoclonal antibody, has been approved in Europe for the treatment of adult patients with active relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), on the basis of previous phase III studies. However, limited data were available on ocrelizumab efficacy in RMS...

Uploaded on: December 3, 2022